Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1042-1049

  Lipshultz, Steven E ^a,b   Miller, Tracie L ^a,b   Scully, Rebecca E ^a   Lipsitz, Stuart R ^c   Rifai, Nader ^d   Silverman, Lewis B ^d,e   Colan, Steven D ^e   Neuberg, Donna S ^d   Dahlberg, Suzanne E ^d   Henkel, Jacqueline M ^a   Asselin, Barbara L ^f   Athale, Uma H ^g   Clavell, Luis A ^j   Laverdier̀e, Caroline ^h   Michon, Bruno ⁱ   Schorin, Marshall A ^k   Sallan, Stephen E ^d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j San Jorge Children's Hospital   (Puerto Rico)

^k INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DOXORUBICIN; RAZOXANE; TROPONIN T;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; C REACTIVE PROTEIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART INJURY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT OUTCOME; TROPONIN T BLOOD LEVEL;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RAZOXANE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84861779336     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3404     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008 (Pubitemid 351521864)
2. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
3. Krischer JP, Cuthbertson DD, Epstein S, et al: Risk factors for early anthracycline clinical cardiotoxicity in children: The pediatric oncology group experience. Prog Pediatr Cardiol 8:83-90, 1997 (Pubitemid 28190025)
4. Nysom K, Holm K, Lipsitz SR, et al: Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 16:545-550, 1998 (Pubitemid 28135597)
5. Barry E, Alvarez JA, Scully RE, et al: Anthracycline-induced cardiotoxicty: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 8:1039-1058, 2007 (Pubitemid 46929299)
6. Lipshultz SE, Alvarez JA, Scully RE: Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-533, 2008 (Pubitemid 351441417)
7. Gianni L, Herman EH, Lipshultz SE, et al: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784, 2008
8. Ganz WI, Sridhar KS, Ganz SS, et al: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53:461-470, 1996 (Pubitemid 26388387)
9. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004 (Pubitemid 38886649)
10. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL ConsortiumProtocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007 (Pubitemid 46220632)
11. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961, 2010
12. Cooper LT, Baughman KL, Feldman AM, et al: The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914-1931, 2007 (Pubitemid 350011209)
13. Braunwald E: Biomarkers in heart failure. N Engl J Med 358:2148-2159, 2008
14. Horacek JM, Tichy M, Pudil R, et al: Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation. Neoplasma 55:532-537, 2008
15. Zethelius B, Berglund L, Sundström J, et al: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358:2107-2116, 2008 (Pubitemid 351679597)
16. Koç M, Bozkurt A, Acartürk E, et al: Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure. Am J Cardiol 101:1157-1162, 2008
17. Lipshultz SE, Somers MJ, Lipsitz SR, et al: Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 112: 79-86, 2003 (Pubitemid 36792933)
18. Lipshultz SE, Rifai N, Sallan SE, et al: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641- 2648, 1997
19. Cardinale D, Sandri MT, Colombo A, et al: Prognostic value of troponin I in cardiac risk stratifi- cation of cancer patients undergoing high-dosechemotherapy. Circulation 109:2749-2754, 2004 (Pubitemid 38737923)
20. Jaffe AS, Ravkilde J, Roberts R, et al: It's time for a change to a troponin standard. Circulation 102:1216-1220, 2000
21. Cardinale D, Sandri MT, Martinoni A, et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517-522, 2000
22. Kistorp C, Raymond I, Pedersen F, et al: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609-1616, 2005 (Pubitemid 40471791)
23. Kragelund C, Grønnin B, Køber L, et al: N-terminal pro-B-type natriuretic peptide and longterm mortality in stable coronary heart disease. N Engl J Med 352:666-675, 2005 (Pubitemid 40239214)
24. Ndrepepa G, Braun S, Niemöller K, et al: Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 112:2102-2107, 2005 (Pubitemid 41475802)
25. Omland T, Persson A, Ng L, et al: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106: 2913-2918, 2002 (Pubitemid 35424741)
26. Bibbins-Domingo K, Gupta R, Na B, et al: N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297:169-176, 2007 (Pubitemid 46089733)
27. Grewal J, McKelvie RS, Persson H, et al: Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 102:733-737, 2008
28. Lorgis L, Zeller M, Dentan G, et al: Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: Prospective observation study. BMJ 338:b1605, 2009
29. Masson S, Latini R: Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. Am J Cardiol 101:56-60, 2008
30. Dini FL, Conti U, Fontanive P, et al: Prognostic value of N-terminal pro-type-b natriuretic peptide and Doppler left ventricular diastolic variables in patients with chronic systolic heart failure stabilized by therapy. Am J Cardiol 102:463-468, 2008
31. Hunt PJ, Yandle TG, Nicholls MG, et al: The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214:1175-1183, 1995
32. Martinez-Rumayor A, Richards AM, Burnett JC, et al: Biology of the natriuretic peptides. Am J Cardiol 101:3-8, 2008
33. Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655-663, 2004 (Pubitemid 38364624)
34. Black S, Kushner I, Samols D: C-reactive protein. J Biol Chem 279:48487-48490, 2004 (Pubitemid 39625721)
35. Singh SK, Suresh MV, Voleti B, et al: The connection between C-reactive protein and atherosclerosis. Ann Med 40:110-120, 2007 (Pubitemid 351640645)
36. Shishehbor MH, Bhatt DL, Topol EJ: Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med 70:634-640, 2003 (Pubitemid 36939964)
37. Todd J, Freese B, Lu A, et al: Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 53:1990-1995, 2007 (Pubitemid 350036054)
38. Sluysmans T, Colan SD: Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 99:445-457, 2005 (Pubitemid 41061136)
39. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, et al: Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics 58:621- 630, 2002
40. Fitzmaurice GM, Lipsitz SR, Ibrahim JG, et al: Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. Biostatistics 7:469-485, 2006 (Pubitemid 43955053)
41. Lipshultz SE: Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 12:1-28, 2000
42. Ratnasamy C, Kinnamon DD, Lipshultz SE, et al: Associations between neurohormonal and in- flammatory activation and heart failure in children. Am Heart J 155:527-533, 2008